Literature DB >> 19690032

18F-FDG PET SUVmax correlates with osteosarcoma histologic response to neoadjuvant chemotherapy: preclinical evaluation in an orthotopic rat model.

Aurélie Dutour1, Anne-Valérie Decouvelaere, Jacques Monteil, Marie-Eve Duclos, Olivier Roualdes, Raphaël Rousseau, Perrine Marec-Bérard.   

Abstract

UNLABELLED: Assessment of osteosarcoma response to neoadjuvant chemotherapy is performed by histopathologic analysis after surgical resection of the primary tumor. The purpose of this study was to evaluate whether (18)F-FDG PET could be a noninvasive surrogate to histopathologic analysis and allow for earlier response evaluation to neoadjuvant chemotherapy in osteosarcoma.
METHODS: Metabolic response to neoadjuvant chemotherapy was assessed in immunocompetent rats with a preestablished orthotopic osteosarcoma using (18)F-FDG PET before and after receiving 2 doses of ifosfamide. Comparison was then made by assessing histologic responses on euthanized animals.
RESULTS: Maximum standardized uptake value (SUVmax) measured by (18)F-FDG PET after 2 doses of chemotherapy was correlated to histologic classification (P < 0.01). An SUVmax less than 15 corresponded to good responders, whereas an SUVmax greater than 15 but less than 20 and an SUVmax greater than 20 corresponded to partial responders or nonresponders, respectively. A 40% decrease in SUVmax between the first and second (18)F-FDG PET scans distinguished between partial and good response to chemotherapy.
CONCLUSION: Determination of SUVmax using semiquantitative (18)F-FDG PET predicts response to neoadjuvant chemotherapy earlier than does histologic analysis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19690032     DOI: 10.2967/jnumed.109.062356

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  4 in total

1.  Assessment of histological response of paediatric bone sarcomas using FDG PET in comparison to morphological volume measurement and standardized MRI parameters.

Authors:  Timm Denecke; Patrick Hundsdörfer; Daniel Misch; Ingo G Steffen; Stefan Schönberger; Christian Furth; Michail Plotkin; Juri Ruf; Hubertus Hautzel; Brigitte Stöver; Regine Kluge; Uta Bierbach; Sylke Otto; James F Beck; Christiane Franzius; Günter Henze; Holger Amthauer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-05-27       Impact factor: 9.236

2.  Does expression of glucose transporter protein-1 relate to prognosis and angiogenesis in osteosarcoma?

Authors:  Tadahiko Kubo; Shoji Shimose; Jun Fujimori; Taisuke Furuta; Koji Arihiro; Mitsuo Ochi
Journal:  Clin Orthop Relat Res       Date:  2014-09-06       Impact factor: 4.176

3.  Comprehensive establishment and characterization of orthoxenograft mouse models of malignant peripheral nerve sheath tumors for personalized medicine.

Authors:  Joan Castellsagué; Bernat Gel; Juana Fernández-Rodríguez; Roger Llatjós; Ignacio Blanco; Yolanda Benavente; Diana Pérez-Sidelnikova; Javier García-Del Muro; Joan Maria Viñals; August Vidal; Rafael Valdés-Mas; Ernest Terribas; Adriana López-Doriga; Miguel Angel Pujana; Gabriel Capellá; Xose S Puente; Eduard Serra; Alberto Villanueva; Conxi Lázaro
Journal:  EMBO Mol Med       Date:  2015-05       Impact factor: 12.137

4.  Current state of oncologic 18F-FDG PET/CT in Japan: A nationwide survey.

Authors:  Hajime Ichikawa; Toyohiro Kato; Kenta Miwa; Takayuki Shibutani; Koichi Okuda; Akio Nagaki; Hiroyuki Tsushima; Masahisa Onoguchi
Journal:  Asia Ocean J Nucl Med Biol       Date:  2021
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.